

LINK PHARMA CHEM LIMITED CIN: L24230GJ1984PLC007540

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs in Lakhs)

	TEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE T	Quarter ended			(Rs in Lakhs)	
Sr. No.	Particulars	30th June 2025	31st March 2025	30th June 2024 (Unaudited)	Year ended 31st March 2025 (Audited)	
		(Unaudited)				
1	Revenue from operations	781.48	644.66	884.63	2,543.34	
	Other income	20.92	11.79	27.16	18.65	
	Total Income (A)	802.40	656.45	911.80	2,561.99	
2	Expenses:					
	Cost of materials consumed	269.69	132.29	499.56	1,121.75	
	Changes in inventories of finished goods and work-in- progress	61.48	194.55	7.63	132.72	
	Employee benefits expense	153.02	133.55	130.81	539.22	
	Finance costs	10.40	14.14	22.03	77.55	
	Depreciation and amortization expense	23.91	23.62	23.54	94.29	
	Power and Fuel	86.36	75.65	84.34	310.82	
	Other Expenses	146.56	130.92	107.85	425.90	
	Total expenses (B)	751.43	704.72	875.76	2,702.24	
3	(Loss)/Profit before tax (C) = (A-B)	50.97	(48.27)	36.03	(140.25	
4	Tax expense:					
	(1) Current tax	2	-	74	-	
	(2) MAT credit recognised	5	(#s)			
	(2) Short/(Excess) Provision of tax relating to earlier Year		2.56	180	2.56	
	(3) Deferred tax	10.78	(15.81)	6.39	(40.08	
	Total tax expense (D)	10.78	(13.25)	6.39	(37.52	
5	(Loss)/Profit for the year/period (E) = (C-D)	40.19	(35.02)	29.64	(102.73	
6	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss					
	Net fair value gain on equity instruments through Other Comprehensive Income	0.32	(0.20)	0.16	(0.06	
	Remeasurement (loss) / gain of the defined benefit plan	(0.65)	(5.66)	1.02	(2.60	
	Income tax effect on above	0.18	1.61	(0.32)	0.73	
	Total other comprehensive income for the year/period, net of tax (F)	(0.15)	(4.25)	0.86	(1.93	
7	Total comprehensive income for the year/period (Net of Tax) (E+F)	40.04	(39.27)	30.50	(104.66	
8	Paid up Equity share capital of Rs 10 each	444.06	444.06	444.06	444.06	
9	Other Equity				822.15	
10	Earnings per equity share (FV of Rs. 10) (Rs.)					
	Basic and Diluted	0.91	(0.79)	0.67	(2.31)	

* VADQIDARA *

ERED OFFICE: Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara, (Gujarat), India).



Notes:

- 1 The above financial results for the quarter ended on June 30, 2025 have been reviewed by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on August 1st, 2025.
- 2 The Company's operations fall under single segment namely "Manufacture and Sale of Chemicals".
- 3 As per the Ind AS 109 'Financial Instruments', the investment of the Company are valued at market prices and the difference between the cost and market value of the investments are accounted as part of Other Income. The break up of the reported figures are arrived as per working given hereunder.

	Quarter ended			Year ended	
Particulars	30th June 2025 (Unaudited)	31st March 2025 (Audited)	30th June 2024 (Unaudited)	31st March 2025 (Audited)	
Other income (A)	20.92	11.79	27.16	18.65	
Fair value Net Gain/(loss) arising on financial asset designated as at FVTPL (B)	18.96	10.28	23.23	9.68	
Adjusted Other Income (A-B)	1.96	1.51	3.93	8.97	

4 The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the relevant financial year.

VADODARA *

For Link Pharma Chem Limited

Satish G. Thakur Chairman & Whole-time Director (DIN: 00292129)

Date: 1st August 2025 Place: Vadodara